CUBE vs PRAX · P/E 25, rev $1.07B vs rev $8.6M
CubeSmart (CUBE) versus Praxis Precision Medicines Inc (PRAX) — a side-by-side from cached financials, not a winner call.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Praxis Precision Medicines Inc (PRAX) is a biotechnology company listed on US.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Latest reported PRAX revenue for 2024-12-31 was $8.6M. Net income was -$58.7M. Revenue was up 249.5% from 2023-12-31 to 2024-12-31. PRAX currently screens at market cap $7.38B.
CUBE currently screens at market cap $9.69B and trailing P/E 25.0. PRAX currently screens at market cap $7.38B.
Not investment advice. Open the CUBE and PRAX stock pages for the full models.
Not investment advice.